<p>Ardelyx, Inc.（納斯達克股票代碼：ARDX - 獲取免費報告）的股價在週五交易中跌破了其 200 日移動平均線。該股的 200 日移動平均價為 7.21 美元，最低交易價為 5.76 美元。Ardelyx 股票最近以 5.85 美元交易，成交量為 2,695,116 股。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>華爾街看好的 3 只低於 20 美元的中盤股</li>
</ul>
<p>多位研究分析師發佈了關於該股的報告。Piper Sandler 將 Ardelyx 股票的評級從 “增持” 調降至 “中性”，並在 7 月 2 日星期二的研究報告中將其目標股價從 15.00 美元降至 7.00 美元。StockNews.com 在 7 月 31 日的報告中將 Ardelyx 股票的評級從 “賣出” 調升至 “持有”。花旗集團將 Ardelyx 的目標股價從 10.00 美元調高至 12.00 美元，並在 8 月 2 日星期五的研究報告中給予該公司 “買入” 評級。HC Wainwright 將 Ardelyx 的目標股價從 10.00 美元調高至 11.00 美元，並在 8 月 5 日星期一的研究報告中給予該股 “買入” 評級。最後，Cantor Fitzgerald 在 6 月 20 日星期四的研究報告中重申了對 Ardelyx 股票的 “增持” 評級。兩位研究分析師對該股進行了持有評級，六位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat 的數據，該股的平均評級為 “中等買入”，共識目標股價為 11.43 美元。</p>
<p><strong>閲讀我們關於 ARDX 的最新股票報告</strong></p>
<h2>Ardelyx 股票表現</h2>
<ul>
<li>2022 年初下滑後，Ardelyx 是否值得買入</li>
</ul>
<p>該公司的五十日移動平均股價為 5.91 美元，兩百日移動平均股價為 7.21 美元。該公司的市值為 13.6 億美元，市盈率為-20.89，貝塔係數為 0.83。公司的資產負債比為 0.66，流動比率為 4.53，速動比率為 4.36。</p>
<p>Ardelyx（納斯達克股票代碼：ARDX - 獲取免費報告）於 8 月 1 日星期四公佈了其季度財報。這家生物製藥公司在該季度報告中每股虧損 0.07 美元，超過了每股虧損 0.11 美元的共識預期 0.04 美元。Ardelyx 的淨利潤率為-31.02%，淨資產收益率為-38.41%。該公司在該季度實現了 7,320 萬美元的營收，超過了分析師對 5503 萬美元的預期。去年同期，該公司每股虧損為 0.08 美元。作為一組，股票研究分析師預計 Ardelyx, Inc.今年將實現每股-0.34 美元的盈利。</p>
<h2>內部人士押注</h2>
<p>另外，首席執行官 Michael Raab 於 7 月 29 日星期一以 5.64 美元的平均價格出售了 30,000 股股票。該交易總價值為 169,200.00 美元。交易完成後，首席執行官在公司擁有 1,260,463 股股票，價值約 7,109,011.32 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過此超鏈接查看。此外，內部人士 David P. Rosenbaum 於 6 月 3 日星期一以 7.00 美元的平均價格出售了 17,872 股 Ardelyx 股票。這些股票的總價值為 125,104.00 美元。交易完成後，該內部人士現在直接持有公司股票 158,502 股，價值 1,109,514 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過此超鏈接訪問。此外，首席執行官 Michael Raab 於 7 月 29 日星期一以 5.64 美元的平均價格出售了 30,000 股公司股票。這些股票的總價值為 169,200.00 美元。交易完成後，首席執行官現在持有公司股票 1,260,463 股，價值約 7,109,011.32 美元。此次交易的披露信息可在此處找到。過去 90 天內，內部人士已出售了價值 1,903,349 美元的 284,411 股公司股票。公司股份的 5.50% 歸內部人士所有。</p>
<h2>Ardelyx 的機構交易</h2>
<p>大型投資者最近增加或減少了對該公司的持股。Eventide Asset Management LLC 在第四季度增持了 Ardelyx 股票，持股增長了 152.5%，現在擁有 680 萬 5494 股這家生物製藥公司的股票，價值 4219.4 萬美元，比上一季度增加了 411 萬 494 股。Redmile Group LLC 在第一季度收購了 Ardelyx 的新股，價值約 1602 萬美元。Millennium Management LLC 在第二季度增持了 Ardelyx 的股份，持股增長了 142.8%，現在擁有 320 萬 3090 股這家生物製藥公司的股票，價值 2373.5 萬美元，比上一季度增加了 188 萬 3995 股。Price T Rowe Associates Inc. MD 在第一季度增持了 Ardelyx 的股份，持股增長了 68.0%，現在擁有 391 萬 3863 股這家生物製藥公司的股票，價值 2857.2 萬美元，比上一季度增加了 158 萬 4597 股。最後，Rubric Capital Management LP 在第四季度增持了 Ardelyx 的股份，持股增長了 60.5%，現在擁有 401 萬 2753 股這家生物製藥公司的股票，價值 2487.9 萬美元，比上一季度增加了 151 萬 2753 股。58.92% 的股份由機構投資者和對沖基金持有。</p>
<h2>關於 Ardelyx（獲取免費報告）</h2>
<p>Ardelyx, Inc.是一家生物製藥公司，致力於在美國和國際市場上發現、開發和銷售治療胃腸和心臟腎臟疾病的藥物。該公司的主要產品候選藥物是 tenapanor，用於治療具有便秘型腸易激綜合徵的患者。</p>
<h2>更多閲讀</h2>
<ul>
<li>五隻我們比 Ardelyx 更喜歡的股票</li>
<li>科技股解析：關於科技的要點</li>
<li>京東盈利驚喜：中國前景好於預期</li>
<li>投資高市盈率成長股</li>
<li>沃倫·巴菲特最近的股票操作：值得關注的熱門買賣</li>
<li>什麼是分紅收割策略，投資者如何從中獲利？</li>
<li>Sea Limited 的電商和金融科技實力推動股價飆升</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關本故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 2024 年科技恐慌：億萬富翁知道的你不知道的（來自 InvestorPlace）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5"/></p>
<h2>現在是否值得投資$1,000 在 Ardelyx？</h2>
<p>在考慮 Ardelyx 之前，您需要聽到這個消息。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單...而 Ardelyx 不在其中。</p>
<p>雖然 Ardelyx 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ARDX

<p>Ardelyx（納斯達克股票代碼：ARDX）股價跌破了其 200 日移動平均線的 0.21 美元，最低交易價為 0.76 美元。分析師對該股褒貶不一，Piper Sandler 將股票評級下調至 “中性”，並降低目標價。相反，花旗集團和 HC Wainwright 則上調了評級。財務數據顯示季度營收增長了 228.3%，但每股收益仍為負值，為-0.07 美元。近期有大量內部人士減持股份，機構投資者也在積極交易。該股的平均評級為 “中等買入”，共識目標價為 0.43 美元</p>

<p>Shares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $7.21 and traded as low as $5.76. Ardelyx shares last traded at $5.85, with a volume of 2,695,116 shares.</p>
<div class="lb-trans"><p>Ardelyx, Inc.（納斯達克股票代碼：ARDX - 獲取免費報告）的股價在週五交易中跌破了其 200 日移動平均線。該股的 200 日移動平均價為 7.21 美元，最低交易價為 5.76 美元。Ardelyx 股票最近以 5.85 美元交易，成交量為 2,695,116 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<ul>
<li>3 mid-caps under $20 that Wall Street loves</li>
</ul>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
<ul>
<li>華爾街看好的 3 只低於 20 美元的中盤股</li>
</ul>
</div><p>A number of research analysts have issued reports on the stock. Piper Sandler cut shares of Ardelyx from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and decreased their target price for the stock from $15.00 to $7.00 in a research report on Tuesday, July 2nd. StockNews.com raised Ardelyx from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, July 31st. Citigroup lifted their target price on Ardelyx from $10.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 2nd. HC Wainwright increased their price target on Ardelyx from $10.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, August 5th. Finally, Cantor Fitzgerald restated an &#34;overweight&#34; rating on shares of Ardelyx in a research note on Thursday, June 20th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $11.43.</p>
<div class="lb-trans"><p>多位研究分析師發佈了關於該股的報告。Piper Sandler 將 Ardelyx 股票的評級從 “增持” 調降至 “中性”，並在 7 月 2 日星期二的研究報告中將其目標股價從 15.00 美元降至 7.00 美元。StockNews.com 在 7 月 31 日的報告中將 Ardelyx 股票的評級從 “賣出” 調升至 “持有”。花旗集團將 Ardelyx 的目標股價從 10.00 美元調高至 12.00 美元，並在 8 月 2 日星期五的研究報告中給予該公司 “買入” 評級。HC Wainwright 將 Ardelyx 的目標股價從 10.00 美元調高至 11.00 美元，並在 8 月 5 日星期一的研究報告中給予該股 “買入” 評級。最後，Cantor Fitzgerald 在 6 月 20 日星期四的研究報告中重申了對 Ardelyx 股票的 “增持” 評級。兩位研究分析師對該股進行了持有評級，六位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat 的數據，該股的平均評級為 “中等買入”，共識目標股價為 11.43 美元。</p>
</div><p><strong>Read Our Latest Stock Report on ARDX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ARDX 的最新股票報告</strong></p>
</div><h2>Ardelyx Stock Performance</h2>
<ul>
<li>Is Ardelyx is A Buy After Slip in Early 2022</li>
</ul>
<div class="lb-trans"><h2>Ardelyx 股票表現</h2>
<ul>
<li>2022 年初下滑後，Ardelyx 是否值得買入</li>
</ul>
</div><p>The company has a fifty day moving average price of $5.91 and a two-hundred day moving average price of $7.21. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -20.89 and a beta of 0.83. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.53 and a quick ratio of 4.36.</p>
<div class="lb-trans"><p>該公司的五十日移動平均股價為 5.91 美元，兩百日移動平均股價為 7.21 美元。該公司的市值為 13.6 億美元，市盈率為-20.89，貝塔係數為 0.83。公司的資產負債比為 0.66，流動比率為 4.53，速動比率為 4.36。</p>
</div><p>Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. Ardelyx had a negative net margin of 31.02% and a negative return on equity of 38.41%. The company had revenue of $73.20 million during the quarter, compared to analyst estimates of $55.03 million. During the same quarter last year, the firm posted ($0.08) EPS. The business's revenue for the quarter was up 228.3% on a year-over-year basis. As a group, equities research analysts expect that Ardelyx, Inc. will post -0.34 EPS for the current year.</p>
<div class="lb-trans"><p>Ardelyx（納斯達克股票代碼：ARDX - 獲取免費報告）於 8 月 1 日星期四公佈了其季度財報。這家生物製藥公司在該季度報告中每股虧損 0.07 美元，超過了每股虧損 0.11 美元的共識預期 0.04 美元。Ardelyx 的淨利潤率為-31.02%，淨資產收益率為-38.41%。該公司在該季度實現了 7,320 萬美元的營收，超過了分析師對 5503 萬美元的預期。去年同期，該公司每股虧損為 0.08 美元。作為一組，股票研究分析師預計 Ardelyx, Inc.今年將實現每股-0.34 美元的盈利。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士押注</h2>
</div><p>In other news, CEO Michael Raab sold 30,000 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $5.64, for a total transaction of $169,200.00. Following the completion of the sale, the chief executive officer now owns 1,260,463 shares in the company, valued at approximately $7,109,011.32. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. In other news, insider David P. Rosenbaum sold 17,872 shares of Ardelyx stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $7.00, for a total value of $125,104.00. Following the transaction, the insider now directly owns 158,502 shares of the company's stock, valued at $1,109,514. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael Raab sold 30,000 shares of the company's stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $5.64, for a total transaction of $169,200.00. Following the completion of the sale, the chief executive officer now owns 1,260,463 shares of the company's stock, valued at approximately $7,109,011.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 284,411 shares of company stock worth $1,903,349. 5.50% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>另外，首席執行官 Michael Raab 於 7 月 29 日星期一以 5.64 美元的平均價格出售了 30,000 股股票。該交易總價值為 169,200.00 美元。交易完成後，首席執行官在公司擁有 1,260,463 股股票，價值約 7,109,011.32 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過此超鏈接查看。此外，內部人士 David P. Rosenbaum 於 6 月 3 日星期一以 7.00 美元的平均價格出售了 17,872 股 Ardelyx 股票。這些股票的總價值為 125,104.00 美元。交易完成後，該內部人士現在直接持有公司股票 158,502 股，價值 1,109,514 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過此超鏈接訪問。此外，首席執行官 Michael Raab 於 7 月 29 日星期一以 5.64 美元的平均價格出售了 30,000 股公司股票。這些股票的總價值為 169,200.00 美元。交易完成後，首席執行官現在持有公司股票 1,260,463 股，價值約 7,109,011.32 美元。此次交易的披露信息可在此處找到。過去 90 天內，內部人士已出售了價值 1,903,349 美元的 284,411 股公司股票。公司股份的 5.50% 歸內部人士所有。</p>
</div><h2>Institutional Trading of Ardelyx</h2>
<div class="lb-trans"><h2>Ardelyx 的機構交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Eventide Asset Management LLC grew its holdings in shares of Ardelyx by 152.5% during the fourth quarter. Eventide Asset Management LLC now owns 6,805,494 shares of the biopharmaceutical company's stock valued at $42,194,000 after buying an additional 4,110,494 shares in the last quarter. Redmile Group LLC acquired a new stake in Ardelyx during the 1st quarter worth about $16,020,000. Millennium Management LLC grew its stake in Ardelyx by 142.8% during the 2nd quarter. Millennium Management LLC now owns 3,203,090 shares of the biopharmaceutical company's stock valued at $23,735,000 after acquiring an additional 1,883,995 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Ardelyx by 68.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,913,863 shares of the biopharmaceutical company's stock valued at $28,572,000 after purchasing an additional 1,584,597 shares during the period. Finally, Rubric Capital Management LP lifted its position in shares of Ardelyx by 60.5% in the fourth quarter. Rubric Capital Management LP now owns 4,012,753 shares of the biopharmaceutical company's stock worth $24,879,000 after purchasing an additional 1,512,753 shares in the last quarter. 58.92% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該公司的持股。Eventide Asset Management LLC 在第四季度增持了 Ardelyx 股票，持股增長了 152.5%，現在擁有 680 萬 5494 股這家生物製藥公司的股票，價值 4219.4 萬美元，比上一季度增加了 411 萬 494 股。Redmile Group LLC 在第一季度收購了 Ardelyx 的新股，價值約 1602 萬美元。Millennium Management LLC 在第二季度增持了 Ardelyx 的股份，持股增長了 142.8%，現在擁有 320 萬 3090 股這家生物製藥公司的股票，價值 2373.5 萬美元，比上一季度增加了 188 萬 3995 股。Price T Rowe Associates Inc. MD 在第一季度增持了 Ardelyx 的股份，持股增長了 68.0%，現在擁有 391 萬 3863 股這家生物製藥公司的股票，價值 2857.2 萬美元，比上一季度增加了 158 萬 4597 股。最後，Rubric Capital Management LP 在第四季度增持了 Ardelyx 的股份，持股增長了 60.5%，現在擁有 401 萬 2753 股這家生物製藥公司的股票，價值 2487.9 萬美元，比上一季度增加了 151 萬 2753 股。58.92% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>About Ardelyx (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Ardelyx（獲取免費報告）</h2>
</div><p>Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.</p>
<div class="lb-trans"><p>Ardelyx, Inc.是一家生物製藥公司，致力於在美國和國際市場上發現、開發和銷售治療胃腸和心臟腎臟疾病的藥物。該公司的主要產品候選藥物是 tenapanor，用於治療具有便秘型腸易激綜合徵的患者。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Ardelyx</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>JD.com Earnings Surprise: China’s Outlook Better Than Expected</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch</li>
<li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li>
<li>Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge</li>
</ul>
<div class="lb-trans"><h2>更多閲讀</h2>
<ul>
<li>五隻我們比 Ardelyx 更喜歡的股票</li>
<li>科技股解析：關於科技的要點</li>
<li>京東盈利驚喜：中國前景好於預期</li>
<li>投資高市盈率成長股</li>
<li>沃倫·巴菲特最近的股票操作：值得關注的熱門買賣</li>
<li>什麼是分紅收割策略，投資者如何從中獲利？</li>
<li>Sea Limited 的電商和金融科技實力推動股價飆升</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關本故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ The 2024 Tech Panic: What Billionaires Know That You Don’t (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 2024 年科技恐慌：億萬富翁知道的你不知道的（來自 InvestorPlace）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9179&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Ardelyx right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Ardelyx？</h2>
</div><p>Before you consider Ardelyx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ardelyx 之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單...而 Ardelyx 不在其中。</p>
</div><p>While Ardelyx currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ardelyx 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Ardelyx（納斯達克：ARDX）股價跌破 200 日移動平均線 7.21 美元